BioCentury
ARTICLE | Top Story

GTx plummets on Phase III enobosarm data

August 19, 2013 11:30 PM UTC

GTx Inc. (NASDAQ:GTXI) shed $2.72 (66%) to $1.43 on Monday after its once-daily oral enobosarm failed in a pair of Phase III trials to prevent and treat muscle wasting in patients with non-small cell ...